MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Price & Overview
NASDAQ:MLTX • KY61559X1045
Current stock price
The current stock price of MLTX is 17.89 USD. Today MLTX is down by -2.45%. In the past month the price increased by 9.96%. In the past year, price decreased by -54.62%.
MLTX Key Statistics
- Market Cap
- 1.283B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.52
- Dividend Yield
- N/A
MLTX Stock Performance
MLTX Stock Chart
MLTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MLTX. When comparing the yearly performance of all stocks, MLTX is a bad performer in the overall market: 87% of all stocks are doing better.
MLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLTX. The financial health of MLTX is average, but there are quite some concerns on its profitability.
MLTX Earnings
MLTX Forecast & Estimates
23 analysts have analysed MLTX and the average price target is 30.19 USD. This implies a price increase of 68.76% is expected in the next year compared to the current price of 17.89.
MLTX Groups
Sector & Classification
MLTX Financial Highlights
Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -86.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.56% | ||
| ROE | -74.66% | ||
| Debt/Equity | 0.24 |
MLTX Ownership
MLTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MLTX
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
IPO: 2020-10-20
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG CH
Employees: 130
Phone: 41415108022
MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ
Can you describe the business of MOONLAKE IMMUNOTHERAPEUTICS?
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Can you provide the latest stock price for MOONLAKE IMMUNOTHERAPEUTICS?
The current stock price of MLTX is 17.89 USD. The price decreased by -2.45% in the last trading session.
Does MLTX stock pay dividends?
MLTX does not pay a dividend.
How is the ChartMill rating for MOONLAKE IMMUNOTHERAPEUTICS?
MLTX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy MLTX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MLTX.
What is MOONLAKE IMMUNOTHERAPEUTICS worth?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a market capitalization of 1.28B USD. This makes MLTX a Small Cap stock.